NASDAQ$URGN
UroGen Pharma Ltd · Q1 2022 earnings
Q1 2022 earnings · · Investor relations
Briefing
UroGen reported an increase in Jelmyto net product revenue and advanced clinical programs.
UroGen Pharma reported first quarter 2022 financial results, highlighted by an 81% increase in Jelmyto net product revenue compared to Q1 2021, reaching $13.6 million. The company also progressed its clinical programs with the ongoing Phase 3 ENVISION trial for UGN-102 and the initiation of a Phase 1 clinical trial for UGN-301.
- Jelmyto net product revenue increased by 81% year-over-year, reaching $13.6 million in Q1 2022.
- Enrollment is ongoing for the UGN-102 Phase 3 ENVISION pivotal trial, with completion expected by the end of 2022.
- A novel, multi-arm Phase 1 clinical trial of UGN-301 in high-grade non-muscle invasive bladder cancer (NMIBC) was initiated.
- Cash, cash equivalents, and marketable securities totaled $137.1 million as of March 31, 2022, including the first tranche of a term loan facility.
Headline financials
Revenue & EPS history
UroGen · Revenue · Quarterly
$13.6M
Revenue by segment
UroGen · $20.9M total across 1 segment · Q3 2023
- JELMYTO$20.9M+29.8%100.0%
Forward guidance
UroGen anticipates full year 2022 net product revenues from Jelmyto to be in the range of $70 to $80 million and full year 2022 operating expenses in the range of $140 to $160 million.
Tailwinds
- Net product revenues from Jelmyto to be in the range of $70 to $80 million.
- Ongoing Phase 3 ENVISION trial for UGN-102 with enrollment expected to be completed by the end of 2022.
- Initiation of Phase 1 clinical trial of UGN-301 in high-grade NMIBC.
- Continued clinical and operational progress.
- Strengthened financial position to support business initiatives.
Headwinds
- Operating expenses in the range of $140 to $160 million, including non-cash share-based compensation expense of $10 to $16 million, subject to market conditions.
- Non-cash financing expense related to the prepaid obligation to RTW Investments in the range of $22 to $26 million, of which approximately $9.1 to $10.4 million will be paid in cash.
- Clinical trial enrollment challenges.
- Potential safety and other complications of clinical trials.
- Complications associated with commercialization activities.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2022
-1.5%
Avg return
Earnings day
-0.9%
Avg return
5 days after
-4.5%
Avg return
30 days after
50%
17 / 34 earnings
Positive
+22.0%
Q3 2025
Best reaction
-28.7%
Q3 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +10.2% | +31.3% | +12.6% | |
| Q4 2025 | -12.4% | -5.7% | -12.7% | |
| Q3 2025 | +22.0% | +22.4% | +19.0% | |
| Q1 2025 | +7.1% | -29.6% | -29.7% | |
| Q4 2024 | +1.0% | +12.7% | +2.9% | |
| Q3 2024 | -0.9% | +4.8% | +0.7% | |
| Q2 2024 | +3.0% | +2.0% | -10.1% | |
| Q1 2024 | +1.8% | +3.8% | -0.2% | |
| Q4 2023 | -17.2% | -14.0% | -13.6% | |
| Q3 2023 | -1.5% | +6.0% | +29.6% | |
| Q2 2023 | +7.1% | +8.0% | -20.0% | |
| Q1 2023 | +4.8% | +2.2% | +1.3% | |
| Q4 2022 | -11.7% | -9.1% | +0.0% | |
| Q3 2022 | -18.8% | -17.2% | -27.6% | |
| Q2 2022 | -4.3% | -5.5% | -11.4% | |
| Q1 2022 | -2.7% | -4.0% | +13.1% | |
| Q4 2021 | -1.9% | -4.4% | -17.3% | |
| Q3 2021 | -28.7% | -37.0% | -46.9% | |
| Q2 2021 | -1.1% | -1.8% | +14.1% | |
| Q1 2021 | -16.3% | -2.9% | -4.7% | |
| Q4 2020 | +2.4% | -0.3% | -5.9% | |
| Q3 2020 | +0.3% | -1.9% | -22.8% | |
| Q2 2020 | +4.4% | -0.9% | -7.7% | |
| Q1 2020 | -0.2% | +2.8% | +13.4% | |
| Q4 2019 | +6.8% | +6.8% | -39.5% | |
| Q3 2019 | +8.0% | +9.7% | +37.9% | |
| Q2 2019 | -1.2% | -0.7% | +2.2% | |
| Q1 2019 | +3.6% | +1.9% | -1.7% | |
| Q4 2018 | +4.1% | +3.3% | -3.8% | |
| Q3 2018 | +0.7% | +1.0% | -0.3% | |
| Q2 2018 | -10.0% | -7.1% | -3.7% | |
| Q1 2018 | +1.8% | +6.0% | -9.9% | |
| Q4 2017 | -5.8% | -7.5% | +3.0% | |
| Q3 2017 | -3.9% | -5.2% | -14.2% | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro